Catfish skin mucus yields promising antibacterial compound
Scientists report they have extracted a compound with powerful antibacterial properties from the skin of farmed African catfish. Although additional testing is necessary to prove the compound is safe and effective for use as future antibiotic, the researchers say it could one day represent a potent new tool against antimicrobial-resistant bacteria such as extended-spectrum beta-lactamase (ESBL) producing E. coli.
Hedmon Okella is a postdoctoral researcher at the University of California, Davis, and led the project.
“The global public health threat due to antimicrobial resistance necessitates the search for safe and effective new antibacterial compounds,” Okella said. “In this case, fish-derived antimicrobial peptides present a promising source of potential leads.”
Okella will present the new research at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, which is being held March 23–26 in San Antonio.
For the study, the researchers extracted several peptides (short chains of amino acids) from African catfish skin mucus and used machine learning algorithms to screen them for potential antibacterial activity. They then chemically synthesized the most promising peptide, called NACAP-II, and tested its efficacy and safety on ESBL-E. coli and mammalian blood cells, respectively.
These tests showed that NACAP-II caused the bacteria to break open, or lyse, without appearing to harm the mammalian blood cells. “Preliminary findings indicate that this promising peptide candidate potentially disrupts the bacterial cell envelope to cause lysis at a very low concentration,” Okella said.
The place where the peptide was found — in the mucus on the skin of farmed African catfish — is not as unlikely as it may seem. As anyone who has tried to hold one can attest, fish are enveloped in a slippery layer of mucus. This mucus is known to protect the fish against infections by physically carrying germs off of the skin and by producing antimicrobial compounds such as the one Okella’s team isolated.
Many existing medicines are based on compounds that were first found in nature, and scientists speculate that marine and aquatic organisms represent a particularly rich — though largely untapped — source of bioactive compounds.
As a next step, the researchers plan to study the peptide’s effects in animal models and explore strategies to produce it inexpensively.
“We are currently utilizing chemical synthesis to upscale the production of this peptide that we believe will one day be of use as drug candidate in the battle against antimicrobial resistance,” Okella said.
Hedmon Okella will present this research from 4:30 to 6:30 p.m. CDT on Sunday, March 24, in the exhibit hall of the Henry B. González Convention Center (Poster Board No. 86) (abstract).
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Guiding grocery carts to shape healthy habits
Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Quantifying how proteins in microbe and host interact
“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.
From the journals: JLR
Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.